Tuberculosis Drug Market By Type of Tuberculosis (Active Tuberculosis and Latent Tuberculosis); By Treatment Type (First Line Drugs (Isoniazid, Rifampicin/ Rifampin, Ethambutol, Pyrazinamide, & Others), Second Line Drugs (Levofloxacin, Moxifloxacin, & Others)); By Route of Administration (Oral, Parenteral); By Dosage Form (Tablets, Capsules, Powder for Solution for Injection, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, and Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Tuberculosis (TB) is an infectious disease that is usually caused by Mycobacterium tuberculosis (MTB) bacteria. Although tuberculosis is known to generally affect the lungs of patient, it can also affect other parts of the body. As this infectious diseases is affecting millions of people worldwide, the increasing bacterial drug resistance is also threatening a rise in TB cases as many drugs are ineffective against TB treatment. Hence, a surging need for new antibiotics to cure TB is encouraging research & development (R&D) institutions to pacify investments, which showcases substantial growth prospects for the global tuberculosis drug market over the forecast period.
Many factors are driving the global tuberculosis drug market but the most important factor is the growing incidences of tuberculosis in developing countries. TB patients can be seen all over the world but according to a survey, 95% deaths from tuberculosis are in developing countries. Hence, higher demand for drugs that can be useful for tuberculosis treatment comes from developing countries. Many companies manufacturing such drugs see developing countries as target markets. However, the concerns pertaining to high cost of treatment is impeding the growth of the global tuberculosis drug market.
The strategic initiatives being undertaken in the global tuberculosis drug market is expected to inflate market growth in the near future. TB Alliance and Macleods forged a commercial partnership for new therapy for highly drug-resistant TB in October 2019. In another instance, the Drug Controller General of India (DCGI) approved an anti-tuberculosis drug pretomanid, called Mylan Secures, under the National Tuberculosis Elimination Program (NTEP) program in July 2020.
The COVID-19 pandemic has led to a tremendous rise in concern about the health of children because coronavirus can rapidly endanger the life of a patient suffering from TB. Regarding lungs, coronavirus and tuberculosis have similar symptoms. Hence, scientists are experimenting with many drugs useful for tuberculosis treatment to see if they can used for the treatment of coronavirus. Absolute Market Insights reports, the global tuberculosis drug market is likely to grow at 5.1% CAGR during the 2021-2029 period, and reach a valuation of US$ 1619.93 Mn by 2029.
Global Tuberculosis Drug Market Revenue & Forecast, (US $ Million), 2015 – 2029
Type of Tuberculosis Outlook:
In the context of different types of tuberculosis, this research report from Absolute Markets Insights on global tuberculosis drug market covers active tuberculosis and latent tuberculosis. In 2020, the active tuberculosis held the larger market share.
During the forecast period, latent tuberculosis category is anticipated to witness substantial growth rate, primarily due to rising awareness of tuberculosis, increasing public awareness about diagnosis and treatment of the disease, along with the growing healthcare expenditure on diagnosis and treatment of latent tuberculosis infection (LTBI). Growing urbanization in developing countries is also leading to more advanced monitoring and screening procedures, contributing to the market growth of this segment. If a person has latent TB, doctor is likely to recommend treatment with medication if the patient is at high risk of developing active TB. For active tuberculosis, the patient has to take antibiotics for at least six to nine months. The exact amount of drugs and length of treatment depends on the age of patient, overall health, possible drug resistance and the body part of patient which has been affected maximum due to the TB infection. LTBI is the early stage of tuberculosis. Its treatment can avoid the advanced stage, called active tuberculosis. Due to this awareness, more people are coming forward for latent tuberculosis treatment.
Treatment Type Outlook:
The treatment type segment in the global tuberculosis drug market report has been broadly segmented into first line drugs and second line drugs. The first line drugs segment has been further segmented into isoniazid, rifampicin/ rifampin, ethambutol, pyrazinamide, and others. The second line drugs segment has been further segmented into levofloxacin, moxifloxacin, and others.
In 2020, first line drugs segment held the largest market share. However, second line drugs are anticipated to witness highest growth rate over the forecast period owing to the rising prevalence of multidrug-resistant TB (MDR TB). The drugs that are useful for tuberculosis treatment are considered as first line treatment and second line treatment is provided on the basis of the severity of illness. Other factors contributing to the market growth of second line drugs segment include increasing incidence of hospital acquired infection and patient's negligence to continue first line treatment regimen.
Route of Administration Outlook:
On the basis of route of administration, the global tuberculosis drug market is segmented into oral administration and parenteral administration. During the forecast period, the parenteral administration category is estimated to progress as the fastest growing market category because many medicines are more effective only when they directly react with blood so that they can counter the infection causing TB more effectively with full force. Medicines administered orally go through saliva and digestive juices before they reach the blood and fight the virus.
Dosage Form Outlook:
The global tuberculosis drug market on the basis of dosage form is segmented into tablets, capsules, powder for solution for injection, and others. In 2020, tablets and capsules segments occupied substantial market share.
During the forecast period, the powder for solution for injection segment is estimated to register highest CAGR. Many times, powdered solutions are mixed with antibiotic liquid and injected directly into the blood stream of a patient, which launches a full-fledged attack on the virus causing tuberculosis. However, many hospitals offer powdered solutions to patients as inhalers. Inhaling powdered solution for the tuberculosis virus is easy as ingestible medicines cannot be effective if the digestive system of patient is not functioning properly. As the drugs in dry powder inhalers (DPI) are stable, they are considered user-friendly when compared to nebulisation which is time consuming, inconvenient, and inefficient. It also requires special equipment. Also inhaled formula goes directly into lungs which is affected most once a person suffers from tuberculosis. Hence, with two ways available to use the powered solutions, the demand as well as market for powdered solutions is growing.
Region Outlook:
In 2020, North America accounted for the largest share in the global tuberculosis drug market. During the forecast period, Asia Pacific region is anticipated to register highest growth rate. Increasing development of medical infrastructure in Asian countries along with intensified investments into research for tuberculosis treatment drugs by the governments of Asian countries is contributing towards the region’s rapid growth. In 2016, some Asian countries that accounted for highest number of total TB patients in this region included China, India, and Indonesia. In recent years, new tuberculosis strains have emerged that are resistant to existing drug regimens. Hence, the treatment has become more difficult. Government of many Asian countries is offering initiatives to boost medical sector, along with incentives for researches on viruses that can cause tuberculosis.
Competitive Landscape Outlook:
The global tuberculosis drug market landscape showcases a highly innovative, competitive, and fragmented landscape. Despite major investments from many big players of medical sector enterprises, most companies do not have a sizable share of the market to influence pricing. Some key players in the global tuberculosis drug market are Brown & Burk, Cadila Pharmaceuticals, Cipla Inc., Fresenius Kabi (Singapore) Pte Ltd, GlaxoSmithKline PLC., Johnson & Johnson Services Inc., LUPIN, Macleods Pharmaceuticals Ltd., Mylan N.V., Novartis AG, Otsuka Pharmaceutical Co. Ltd., RIEMSER Pharma GmbH, Sanofi, Sequella Inc., and Strides Pharma Science Limited amongst others.
Global Tuberculosis Drug Market:
By Type of Tuberculosis
- Active Tuberculosis
- Latent Tuberculosis
By Treatment Type
- First Line Drugs
- Isoniazid
- Rifampicin/ Rifampin
- Ethambutol
- Pyrazinamide
- Others
- Second Line Drugs
- Levofloxacin
- Moxifloxacin
- Others
By Route of Administration
- Oral
- Parenteral
By Dosage Form
- Tablets
- Capsules
- Powder for Solution for Injection
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Tuberculosis Drug Market
6. Market Synopsis:
Tuberculosis Drug Market
7. Tuberculosis Drug Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Tuberculosis Drug Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Tuberculosis Drug Market
7.6. Porter’s Five Force Analysis
7.7. Impact of
Covid-19 on Tuberculosis Drug Market
8. Global Tuberculosis Drug Market Analysis and Forecasts, 2021
– 2029
8.1. Overview
8.1.1. Global
Tuberculosis Drug Market Revenue (US$ Mn)
8.2. Global
Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Type of
Tuberculosis
8.2.1. Active
Tuberculosis
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 – 2020
8.2.1.3. Market Forecast, 2021 – 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 – 2020
8.2.1.5.1.2. Market
Forecast, 2021 – 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2020
8.2.1.5.2.2. Market
Forecast, 2021 – 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2020
8.2.1.5.3.2. Market
Forecast, 2021 – 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2020
8.2.1.5.4.2. Market
Forecast, 2021 – 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 – 2020
8.2.1.5.5.2. Market
Forecast, 2021 – 2029
8.2.2. Latent
Tuberculosis
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 – 2020
8.2.2.3. Market Forecast, 2021 – 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 – 2020
8.2.2.5.1.2. Market
Forecast, 2021 – 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2020
8.2.2.5.2.2. Market
Forecast, 2021 – 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2020
8.2.2.5.3.2. Market
Forecast, 2021 – 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2020
8.2.2.5.4.2. Market
Forecast, 2021 – 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 – 2020
8.2.2.5.5.2. Market
Forecast, 2021 – 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
of Tuberculosis
9. Global Tuberculosis Drug Market Analysis and Forecasts, 2021
– 2029
9.1. Overview
9.2. Global
Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Treatment Type
9.2.1. First
Line Drugs (Definition, Market Estimation and Penetration, 2015 – 2020, Market
Estimation (2015 – 2020), Market Forecast (2021 – 2029), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Isoniazid, Rifampicin/
Rifampin, Ethambutol, Pyrazinamide, Others)
9.2.1.1. Isoniazid
9.2.1.2. Rifampicin/ Rifampin
9.2.1.3. Ethambutol
9.2.1.4. Pyrazinamide
9.2.1.5. Others
9.2.2. Second
Line Drugs (Definition, Market Estimation and Penetration, 2015 – 2020, Market
Estimation (2015 – 2020), Market Forecast (2021 – 2029), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Levofloxacin, Moxifloxacin,
Others)
9.2.2.1. Levofloxacin
9.2.2.2. Moxifloxacin
9.2.2.3. Others
9.3. Key
Segment for Channeling Investments
9.3.1. By
Treatment Type
10. Global Tuberculosis Drug Market Analysis and Forecasts, 2021
– 2029
10.1. Overview
10.2. Global
Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
10.2.1. Oral
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 – 2020
10.2.1.3. Market Forecast, 2021 – 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 – 2020
10.2.1.5.1.2. Market
Forecast, 2021 – 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2020
10.2.1.5.2.2. Market
Forecast, 2021 – 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2020
10.2.1.5.3.2. Market
Forecast, 2021 – 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2020
10.2.1.5.4.2. Market
Forecast, 2021 – 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 – 2020
10.2.1.5.5.2. Market
Forecast, 2021 – 2029
10.2.2. Parenteral
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 – 2020
10.2.2.3. Market Forecast, 2021 – 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 – 2020
10.2.2.5.1.2. Market
Forecast, 2021 – 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2020
10.2.2.5.2.2. Market
Forecast, 2021 – 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2020
10.2.2.5.3.2. Market
Forecast, 2021 – 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2020
10.2.2.5.4.2. Market
Forecast, 2021 – 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 – 2020
10.2.2.5.5.2. Market
Forecast, 2021 – 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
Route of Administration
11. Global Tuberculosis Drug Market Analysis and Forecasts, 2021
– 2029
11.1. Overview
11.2. Global
Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Dosage Form
11.2.1. Tablets
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 – 2020
11.2.1.3. Market Forecast, 2021 – 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 – 2020
11.2.1.5.1.2. Market
Forecast, 2021 – 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2020
11.2.1.5.2.2. Market
Forecast, 2021 – 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2020
11.2.1.5.3.2. Market
Forecast, 2021 – 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2020
11.2.1.5.4.2. Market
Forecast, 2021 – 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 – 2020
11.2.1.5.5.2. Market
Forecast, 2021 – 2029
11.2.2. Capsules
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 – 2020
11.2.2.3. Market Forecast, 2021 – 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 – 2020
11.2.2.5.1.2. Market
Forecast, 2021 – 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 – 2020
11.2.2.5.2.2. Market
Forecast, 2021 – 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 – 2020
11.2.2.5.3.2. Market
Forecast, 2021 – 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 – 2020
11.2.2.5.4.2. Market
Forecast, 2021 – 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 – 2020
11.2.2.5.5.2. Market
Forecast, 2021 – 2029
11.2.3. Powder
for Solution for Injection
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 – 2020
11.2.3.3. Market Forecast, 2021 – 2029
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 – 2020
11.2.3.5.1.2. Market
Forecast, 2021 – 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 – 2020
11.2.3.5.2.2. Market
Forecast, 2021 – 2029
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 – 2020
11.2.3.5.3.2. Market
Forecast, 2021 – 2029
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 – 2020
11.2.3.5.4.2. Market
Forecast, 2021 – 2029
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 – 2020
11.2.3.5.5.2. Market
Forecast, 2021 – 2029
11.2.4. Others
11.2.4.1. Definition
11.2.4.2. Market Estimation and Penetration, 2015 – 2020
11.2.4.3. Market Forecast, 2021 – 2029
11.2.4.4. Compound Annual Growth Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market
Estimation, 2015 – 2020
11.2.4.5.1.2. Market
Forecast, 2021 – 2029
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2015 – 2020
11.2.4.5.2.2. Market
Forecast, 2021 – 2029
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market
Estimation, 2015 – 2020
11.2.4.5.3.2. Market
Forecast, 2021 – 2029
11.2.4.5.4. Middle East and Africa
11.2.4.5.4.1. Market
Estimation, 2015 – 2020
11.2.4.5.4.2. Market
Forecast, 2021 – 2029
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market
Estimation, 2015 – 2020
11.2.4.5.5.2. Market
Forecast, 2021 – 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By
Dosage Form
12. Global Tuberculosis Drug Market Analysis and Forecasts, 2021
– 2029
12.1. Overview
12.2. Global
Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.2.1. Hospital
Pharmacies
12.2.1.1. Definition
12.2.1.2. Market Estimation and Penetration, 2015 – 2020
12.2.1.3. Market Forecast, 2021 – 2029
12.2.1.4. Compound Annual Growth Rate (CAGR)
12.2.1.5. Regional Bifurcation
12.2.1.5.1. North America
12.2.1.5.1.1. Market
Estimation, 2015 – 2020
12.2.1.5.1.2. Market
Forecast, 2021 – 2029
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2015 – 2020
12.2.1.5.2.2. Market
Forecast, 2021 – 2029
12.2.1.5.3. Asia Pacific
12.2.1.5.3.1. Market
Estimation, 2015 – 2020
12.2.1.5.3.2. Market
Forecast, 2021 – 2029
12.2.1.5.4. Middle East and Africa
12.2.1.5.4.1. Market
Estimation, 2015 – 2020
12.2.1.5.4.2. Market
Forecast, 2021 – 2029
12.2.1.5.5. Latin America
12.2.1.5.5.1. Market
Estimation, 2015 – 2020
12.2.1.5.5.2. Market
Forecast, 2021 – 2029
12.2.2. Retail
Pharmacies
12.2.2.1. Definition
12.2.2.2. Market Estimation and Penetration, 2015 – 2020
12.2.2.3. Market Forecast, 2021 – 2029
12.2.2.4. Compound Annual Growth Rate (CAGR)
12.2.2.5. Regional Bifurcation
12.2.2.5.1. North America
12.2.2.5.1.1. Market
Estimation, 2015 – 2020
12.2.2.5.1.2. Market
Forecast, 2021 – 2029
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2015 – 2020
12.2.2.5.2.2. Market
Forecast, 2021 – 2029
12.2.2.5.3. Asia Pacific
12.2.2.5.3.1. Market
Estimation, 2015 – 2020
12.2.2.5.3.2. Market
Forecast, 2021 – 2029
12.2.2.5.4. Middle East and Africa
12.2.2.5.4.1. Market
Estimation, 2015 – 2020
12.2.2.5.4.2. Market
Forecast, 2021 – 2029
12.2.2.5.5. Latin America
12.2.2.5.5.1. Market
Estimation, 2015 – 2020
12.2.2.5.5.2. Market
Forecast, 2021 – 2029
12.2.3. Online
12.2.3.1. Definition
12.2.3.2. Market Estimation and Penetration, 2015 – 2020
12.2.3.3. Market Forecast, 2021 – 2029
12.2.3.4. Compound Annual Growth Rate (CAGR)
12.2.3.5. Regional Bifurcation
12.2.3.5.1. North America
12.2.3.5.1.1. Market
Estimation, 2015 – 2020
12.2.3.5.1.2. Market
Forecast, 2021 – 2029
12.2.3.5.2. Europe
12.2.3.5.2.1. Market
Estimation, 2015 – 2020
12.2.3.5.2.2. Market
Forecast, 2021 – 2029
12.2.3.5.3. Asia Pacific
12.2.3.5.3.1. Market
Estimation, 2015 – 2020
12.2.3.5.3.2. Market
Forecast, 2021 – 2029
12.2.3.5.4. Middle East and Africa
12.2.3.5.4.1. Market
Estimation, 2015 – 2020
12.2.3.5.4.2. Market
Forecast, 2021 – 2029
12.2.3.5.5. Latin America
12.2.3.5.5.1. Market
Estimation, 2015 – 2020
12.2.3.5.5.2. Market
Forecast, 2021 – 2029
12.2.4. Others
12.2.4.1. Definition
12.2.4.2. Market Estimation and Penetration, 2015 – 2020
12.2.4.3. Market Forecast, 2021 – 2029
12.2.4.4. Compound Annual Growth Rate (CAGR)
12.2.4.5. Regional Bifurcation
12.2.4.5.1. North America
12.2.4.5.1.1. Market
Estimation, 2015 – 2020
12.2.4.5.1.2. Market
Forecast, 2021 – 2029
12.2.4.5.2. Europe
12.2.4.5.2.1. Market
Estimation, 2015 – 2020
12.2.4.5.2.2. Market
Forecast, 2021 – 2029
12.2.4.5.3. Asia Pacific
12.2.4.5.3.1. Market
Estimation, 2015 – 2020
12.2.4.5.3.2. Market
Forecast, 2021 – 2029
12.2.4.5.4. Middle East and Africa
12.2.4.5.4.1. Market
Estimation, 2015 – 2020
12.2.4.5.4.2. Market
Forecast, 2021 – 2029
12.2.4.5.5. Latin America
12.2.4.5.5.1. Market
Estimation, 2015 – 2020
12.2.4.5.5.2. Market
Forecast, 2021 – 2029
12.3. Key
Segment for Channeling Investments
12.3.1. By
Distribution Channel
13. North America Tuberculosis Drug Market Analysis and Forecasts,
2020 - 2028
13.1. Overview
13.1.1. North
America Tuberculosis Drug Market Revenue (US$ Mn)
13.2. North
America Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Type of
Tuberculosis
13.2.1. Active
Tuberculosis
13.2.2. Latent
Tuberculosis
13.3. North
America Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Treatment
Type
13.3.1. First
Line Drugs
13.3.1.1. Isoniazid
13.3.1.2. Rifampicin/ Rifampin
13.3.1.3. Ethambutol
13.3.1.4. Pyrazinamide
13.3.1.5. Others
13.3.2. Second
Line Drugs
13.3.2.1. Levofloxacin
13.3.2.2. Moxifloxacin
13.3.2.3. Others
13.4. North
America Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.4.1. Oral
13.4.2. Parenteral
13.5. North
America Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Dosage Form
13.5.1. Tablets
13.5.2. Capsules
13.5.3. Powder
for Solution for Injection
13.5.4. Others
13.6. North
America Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.1. Hospital
Pharmacies
13.6.2. Retail
Pharmacies
13.6.3. Online
13.6.4. Others
13.7. North
America Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1. U.S Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Type of Tuberculosis
13.7.1.1.1. Active Tuberculosis
13.7.1.1.2. Latent Tuberculosis
13.7.1.2. U.S Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
13.7.1.2.1. First Line Drugs
13.7.1.2.1.1. Isoniazid
13.7.1.2.1.2. Rifampicin/
Rifampin
13.7.1.2.1.3. Ethambutol
13.7.1.2.1.4. Pyrazinamide
13.7.1.2.1.5. Others
13.7.1.2.2. Second Line Drugs
13.7.1.2.2.1. Levofloxacin
13.7.1.2.2.2. Moxifloxacin
13.7.1.2.2.3. Others
13.7.1.3. U.S Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
13.7.1.3.1. Oral
13.7.1.3.2. Parenteral
13.7.1.4. U.S Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
13.7.1.4.1. Tablets
13.7.1.4.2. Capsules
13.7.1.4.3. Powder for Solution for Injection
13.7.1.4.4. Others
13.7.1.5. U.S Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
13.7.1.5.1. Hospital Pharmacies
13.7.1.5.2. Retail Pharmacies
13.7.1.5.3. Online
13.7.1.5.4. Others
13.7.2. Canada
13.7.2.1. Canada Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
13.7.2.1.1. Active Tuberculosis
13.7.2.1.2. Latent Tuberculosis
13.7.2.2. Canada Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
13.7.2.2.1. First Line Drugs
13.7.2.2.1.1. Isoniazid
13.7.2.2.1.2. Rifampicin/
Rifampin
13.7.2.2.1.3. Ethambutol
13.7.2.2.1.4. Pyrazinamide
13.7.2.2.1.5. Others
13.7.2.2.2. Second Line Drugs
13.7.2.2.2.1. Levofloxacin
13.7.2.2.2.2. Moxifloxacin
13.7.2.2.2.3. Others
13.7.2.3. Canada Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.7.2.3.1. Oral
13.7.2.3.2. Parenteral
13.7.2.4. Canada Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
13.7.2.4.1. Tablets
13.7.2.4.2. Capsules
13.7.2.4.3. Powder for Solution for Injection
13.7.2.4.4. Others
13.7.2.5. Canada Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.7.2.5.1. Hospital Pharmacies
13.7.2.5.2. Retail Pharmacies
13.7.2.5.3. Online
13.7.2.5.4. Others
13.7.3. Mexico
13.7.3.1. Mexico Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
13.7.3.1.1. Active Tuberculosis
13.7.3.1.2. Latent Tuberculosis
13.7.3.2. Mexico Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
13.7.3.2.1. First Line Drugs
13.7.3.2.1.1. Isoniazid
13.7.3.2.1.2. Rifampicin/
Rifampin
13.7.3.2.1.3. Ethambutol
13.7.3.2.1.4. Pyrazinamide
13.7.3.2.1.5. Others
13.7.3.2.2. Second Line Drugs
13.7.3.2.2.1. Levofloxacin
13.7.3.2.2.2. Moxifloxacin
13.7.3.2.2.3. Others
13.7.3.3. Mexico Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.7.3.3.1. Oral
13.7.3.3.2. Parenteral
13.7.3.4. Mexico Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
13.7.3.4.1. Tablets
13.7.3.4.2. Capsules
13.7.3.4.3. Powder for Solution for Injection
13.7.3.4.4. Others
13.7.3.5. Mexico Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.7.3.5.1. Hospital Pharmacies
13.7.3.5.2. Retail Pharmacies
13.7.3.5.3. Online
13.7.3.5.4. Others
13.7.4. Rest of
North America
13.7.4.1. Rest of North America Tuberculosis Drug Market Revenue (US$
Mn) and Forecasts, By Type of Tuberculosis
13.7.4.1.1. Active Tuberculosis
13.7.4.1.2. Latent Tuberculosis
13.7.4.2. Rest of North America Tuberculosis Drug Market Revenue (US$
Mn) and Forecasts, By Treatment Type
13.7.4.2.1. First Line Drugs
13.7.4.2.1.1. Isoniazid
13.7.4.2.1.2. Rifampicin/
Rifampin
13.7.4.2.1.3. Ethambutol
13.7.4.2.1.4. Pyrazinamide
13.7.4.2.1.5. Others
13.7.4.2.2. Second Line Drugs
13.7.4.2.2.1. Levofloxacin
13.7.4.2.2.2. Moxifloxacin
13.7.4.2.2.3. Others
13.7.4.3. Rest of North America Tuberculosis Drug Market Revenue (US$
Mn) and Forecasts, By Route of Administration
13.7.4.3.1. Oral
13.7.4.3.2. Parenteral
13.7.4.4. Rest of North America Tuberculosis Drug Market Revenue (US$
Mn) and Forecasts, By Dosage Form
13.7.4.4.1. Tablets
13.7.4.4.2. Capsules
13.7.4.4.3. Powder for Solution for Injection
13.7.4.4.4. Others
13.7.4.5. Rest of North America Tuberculosis Drug Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.7.4.5.1. Hospital Pharmacies
13.7.4.5.2. Retail Pharmacies
13.7.4.5.3. Online
13.7.4.5.4. Others
13.8. Key
Segment for Channeling Investments
13.8.1. By
Country
13.8.2. By Type
of Tuberculosis
13.8.3. By
Treatment Type
13.8.4. By
Route of Administration
13.8.5. By
Dosage Form
13.8.6. By
Distribution Channel
14. Europe Tuberculosis Drug Market Analysis and Forecasts, 2020
- 2028
14.1. Overview
14.1.1. Europe
Tuberculosis Drug Market Revenue (US$ Mn)
14.2. Europe
Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Type of
Tuberculosis
14.2.1. Active
Tuberculosis
14.2.2. Latent
Tuberculosis
14.3. Europe
Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Treatment Type
14.3.1. First
Line Drugs
14.3.1.1. Isoniazid
14.3.1.2. Rifampicin/ Rifampin
14.3.1.3. Ethambutol
14.3.1.4. Pyrazinamide
14.3.1.5. Others
14.3.2. Second
Line Drugs
14.3.2.1. Levofloxacin
14.3.2.2. Moxifloxacin
14.3.2.3. Others
14.4. Europe
Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.4.1. Oral
14.4.2. Parenteral
14.5. Europe
Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Dosage Form
14.5.1. Tablets
14.5.2. Capsules
14.5.3. Powder
for Solution for Injection
14.5.4. Others
14.6. Europe
Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.6.1. Hospital
Pharmacies
14.6.2. Retail
Pharmacies
14.6.3. Online
14.6.4. Others
14.7. Europe
Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Country
14.7.1. France
14.7.1.1. France Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
14.7.1.1.1. Active Tuberculosis
14.7.1.1.2. Latent Tuberculosis
14.7.1.2. France Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
14.7.1.2.1. First Line Drugs
14.7.1.2.1.1. Isoniazid
14.7.1.2.1.2. Rifampicin/
Rifampin
14.7.1.2.1.3. Ethambutol
14.7.1.2.1.4. Pyrazinamide
14.7.1.2.1.5. Others
14.7.1.2.2. Second Line Drugs
14.7.1.2.2.1. Levofloxacin
14.7.1.2.2.2. Moxifloxacin
14.7.1.2.2.3. Others
14.7.1.3. France Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.7.1.3.1. Oral
14.7.1.3.2. Parenteral
14.7.1.4. France Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
14.7.1.4.1. Tablets
14.7.1.4.2. Capsules
14.7.1.4.3. Powder for Solution for Injection
14.7.1.4.4. Others
14.7.1.5. France Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.7.1.5.1. Hospital Pharmacies
14.7.1.5.2. Retail Pharmacies
14.7.1.5.3. Online
14.7.1.5.4. Others
14.7.2. The UK
14.7.2.1. The UK Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
14.7.2.1.1. Active Tuberculosis
14.7.2.1.2. Latent Tuberculosis
14.7.2.2. The UK Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
14.7.2.2.1. First Line Drugs
14.7.2.2.1.1. Isoniazid
14.7.2.2.1.2. Rifampicin/
Rifampin
14.7.2.2.1.3. Ethambutol
14.7.2.2.1.4. Pyrazinamide
14.7.2.2.1.5. Others
14.7.2.2.2. Second Line Drugs
14.7.2.2.2.1. Levofloxacin
14.7.2.2.2.2. Moxifloxacin
14.7.2.2.2.3. Others
14.7.2.3. The UK Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.7.2.3.1. Oral
14.7.2.3.2. Parenteral
14.7.2.4. The UK Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
14.7.2.4.1. Tablets
14.7.2.4.2. Capsules
14.7.2.4.3. Powder for Solution for Injection
14.7.2.4.4. Others
14.7.2.5. The UK Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.7.2.5.1. Hospital Pharmacies
14.7.2.5.2. Retail Pharmacies
14.7.2.5.3. Online
14.7.2.5.4. Others
14.7.3. Spain
14.7.3.1. Spain Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Type of Tuberculosis
14.7.3.1.1. Active Tuberculosis
14.7.3.1.2. Latent Tuberculosis
14.7.3.2. Spain Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
14.7.3.2.1. First Line Drugs
14.7.3.2.1.1. Isoniazid
14.7.3.2.1.2. Rifampicin/
Rifampin
14.7.3.2.1.3. Ethambutol
14.7.3.2.1.4. Pyrazinamide
14.7.3.2.1.5. Others
14.7.3.2.2. Second Line Drugs
14.7.3.2.2.1. Levofloxacin
14.7.3.2.2.2. Moxifloxacin
14.7.3.2.2.3. Others
14.7.3.3. Spain Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
14.7.3.3.1. Oral
14.7.3.3.2. Parenteral
14.7.3.4. Spain Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
14.7.3.4.1. Tablets
14.7.3.4.2. Capsules
14.7.3.4.3. Powder for Solution for Injection
14.7.3.4.4. Others
14.7.3.5. Spain Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
14.7.3.5.1. Hospital Pharmacies
14.7.3.5.2. Retail Pharmacies
14.7.3.5.3. Online
14.7.3.5.4. Others
14.7.4. Germany
14.7.4.1. Germany Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
14.7.4.1.1. Active Tuberculosis
14.7.4.1.2. Latent Tuberculosis
14.7.4.2. Germany Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
14.7.4.2.1. First Line Drugs
14.7.4.2.1.1. Isoniazid
14.7.4.2.1.2. Rifampicin/
Rifampin
14.7.4.2.1.3. Ethambutol
14.7.4.2.1.4. Pyrazinamide
14.7.4.2.1.5. Others
14.7.4.2.2. Second Line Drugs
14.7.4.2.2.1. Levofloxacin
14.7.4.2.2.2. Moxifloxacin
14.7.4.2.2.3. Others
14.7.4.3. Germany Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.7.4.3.1. Oral
14.7.4.3.2. Parenteral
14.7.4.4. Germany Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
14.7.4.4.1. Tablets
14.7.4.4.2. Capsules
14.7.4.4.3. Powder for Solution for Injection
14.7.4.4.4. Others
14.7.4.5. Germany Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.7.4.5.1. Hospital Pharmacies
14.7.4.5.2. Retail Pharmacies
14.7.4.5.3. Online
14.7.4.5.4. Others
14.7.5. Italy
14.7.5.1. Italy Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Type of Tuberculosis
14.7.5.1.1. Active Tuberculosis
14.7.5.1.2. Latent Tuberculosis
14.7.5.2. Italy Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
14.7.5.2.1. First Line Drugs
14.7.5.2.1.1. Isoniazid
14.7.5.2.1.2. Rifampicin/
Rifampin
14.7.5.2.1.3. Ethambutol
14.7.5.2.1.4. Pyrazinamide
14.7.5.2.1.5. Others
14.7.5.2.2. Second Line Drugs
14.7.5.2.2.1. Levofloxacin
14.7.5.2.2.2. Moxifloxacin
14.7.5.2.2.3. Others
14.7.5.3. Italy Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
14.7.5.3.1. Oral
14.7.5.3.2. Parenteral
14.7.5.4. Italy Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
14.7.5.4.1. Tablets
14.7.5.4.2. Capsules
14.7.5.4.3. Powder for Solution for Injection
14.7.5.4.4. Others
14.7.5.5. Italy Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
14.7.5.5.1. Hospital Pharmacies
14.7.5.5.2. Retail Pharmacies
14.7.5.5.3. Online
14.7.5.5.4. Others
14.7.6. Nordic
Countries
14.7.6.1. Nordic Countries Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
14.7.6.1.1. Active Tuberculosis
14.7.6.1.2. Latent Tuberculosis
14.7.6.2. Nordic Countries Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
14.7.6.2.1. First Line Drugs
14.7.6.2.1.1. Isoniazid
14.7.6.2.1.2. Rifampicin/
Rifampin
14.7.6.2.1.3. Ethambutol
14.7.6.2.1.4. Pyrazinamide
14.7.6.2.1.5. Others
14.7.6.2.2. Second Line Drugs
14.7.6.2.2.1. Levofloxacin
14.7.6.2.2.2. Moxifloxacin
14.7.6.2.2.3. Others
14.7.6.3. Nordic Countries Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.7.6.3.1. Oral
14.7.6.3.2. Parenteral
14.7.6.4. Nordic Countries Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
14.7.6.4.1. Tablets
14.7.6.4.2. Capsules
14.7.6.4.3. Powder for Solution for Injection
14.7.6.4.4. Others
14.7.6.5. Nordic Countries Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.7.6.5.1. Hospital Pharmacies
14.7.6.5.2. Retail Pharmacies
14.7.6.5.3. Online
14.7.6.5.4. Others
14.7.6.6. Nordic Countries Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux
Union
14.7.7.1. Benelux Union Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
14.7.7.1.1. Active Tuberculosis
14.7.7.1.2. Latent Tuberculosis
14.7.7.2. Benelux Union Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
14.7.7.2.1. First Line Drugs
14.7.7.2.1.1. Isoniazid
14.7.7.2.1.2. Rifampicin/
Rifampin
14.7.7.2.1.3. Ethambutol
14.7.7.2.1.4. Pyrazinamide
14.7.7.2.1.5. Others
14.7.7.2.2. Second Line Drugs
14.7.7.2.2.1. Levofloxacin
14.7.7.2.2.2. Moxifloxacin
14.7.7.2.2.3. Others
14.7.7.3. Benelux Union Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.7.7.3.1. Oral
14.7.7.3.2. Parenteral
14.7.7.4. Benelux Union Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
14.7.7.4.1. Tablets
14.7.7.4.2. Capsules
14.7.7.4.3. Powder for Solution for Injection
14.7.7.4.4. Others
14.7.7.5. Benelux Union Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.7.7.5.1. Hospital Pharmacies
14.7.7.5.2. Retail Pharmacies
14.7.7.5.3. Online
14.7.7.5.4. Others
14.7.7.6. Benelux Union Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of
Europe
14.7.8.1. Rest of Europe Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
14.7.8.1.1. Active Tuberculosis
14.7.8.1.2. Latent Tuberculosis
14.7.8.2. Rest of Europe Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
14.7.8.2.1. First Line Drugs
14.7.8.2.1.1. Isoniazid
14.7.8.2.1.2. Rifampicin/
Rifampin
14.7.8.2.1.3. Ethambutol
14.7.8.2.1.4. Pyrazinamide
14.7.8.2.1.5. Others
14.7.8.2.2. Second Line Drugs
14.7.8.2.2.1. Levofloxacin
14.7.8.2.2.2. Moxifloxacin
14.7.8.2.2.3. Others
14.7.8.3. Rest of Europe Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.7.8.3.1. Oral
14.7.8.3.2. Parenteral
14.7.8.4. Rest of Europe Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
14.7.8.4.1. Tablets
14.7.8.4.2. Capsules
14.7.8.4.3. Powder for Solution for Injection
14.7.8.4.4. Others
14.7.8.5. Rest of Europe Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.7.8.5.1. Hospital Pharmacies
14.7.8.5.2. Retail Pharmacies
14.7.8.5.3. Online
14.7.8.5.4. Others
14.8. Key
Segment for Channeling Investments
14.8.1. By
Country
14.8.2. By Type
of Tuberculosis
14.8.3. By
Treatment Type
14.8.4. By
Route of Administration
14.8.5. By
Dosage Form
14.8.6. By
Distribution Channel
15. Asia Pacific Tuberculosis Drug Market Analysis and Forecasts,
2020 - 2028
15.1. Overview
15.1.1. Asia
Pacific Tuberculosis Drug Market Revenue (US$ Mn)
15.2. Asia
Pacific Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Type of
Tuberculosis
15.2.1. Active
Tuberculosis
15.2.2. Latent
Tuberculosis
15.3. Asia
Pacific Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Treatment
Type
15.3.1. First
Line Drugs
15.3.1.1. Isoniazid
15.3.1.2. Rifampicin/ Rifampin
15.3.1.3. Ethambutol
15.3.1.4. Pyrazinamide
15.3.1.5. Others
15.3.2. Second
Line Drugs
15.3.2.1. Levofloxacin
15.3.2.2. Moxifloxacin
15.3.2.3. Others
15.4. Asia
Pacific Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.4.1. Oral
15.4.2. Parenteral
15.5. Asia
Pacific Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Dosage Form
15.5.1. Tablets
15.5.2. Capsules
15.5.3. Powder
for Solution for Injection
15.5.4. Others
15.6. Asia
Pacific Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.6.1. Hospital
Pharmacies
15.6.2. Retail
Pharmacies
15.6.3. Online
15.6.4. Others
15.7. Asia
Pacific Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1. China Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Type of Tuberculosis
15.7.1.1.1. Active Tuberculosis
15.7.1.1.2. Latent Tuberculosis
15.7.1.2. China Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
15.7.1.2.1. First Line Drugs
15.7.1.2.1.1. Isoniazid
15.7.1.2.1.2. Rifampicin/
Rifampin
15.7.1.2.1.3. Ethambutol
15.7.1.2.1.4. Pyrazinamide
15.7.1.2.1.5. Others
15.7.1.2.2. Second Line Drugs
15.7.1.2.2.1. Levofloxacin
15.7.1.2.2.2. Moxifloxacin
15.7.1.2.2.3. Others
15.7.1.3. China Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.7.1.3.1. Oral
15.7.1.3.2. Parenteral
15.7.1.4. China Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
15.7.1.4.1. Tablets
15.7.1.4.2. Capsules
15.7.1.4.3. Powder for Solution for Injection
15.7.1.4.4. Others
15.7.1.5. China Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
15.7.1.5.1. Hospital Pharmacies
15.7.1.5.2. Retail Pharmacies
15.7.1.5.3. Online
15.7.1.5.4. Others
15.7.2. Japan
15.7.2.1. Japan Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Type of Tuberculosis
15.7.2.1.1. Active Tuberculosis
15.7.2.1.2. Latent Tuberculosis
15.7.2.2. Japan Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
15.7.2.2.1. First Line Drugs
15.7.2.2.1.1. Isoniazid
15.7.2.2.1.2. Rifampicin/
Rifampin
15.7.2.2.1.3. Ethambutol
15.7.2.2.1.4. Pyrazinamide
15.7.2.2.1.5. Others
15.7.2.2.2. Second Line Drugs
15.7.2.2.2.1. Levofloxacin
15.7.2.2.2.2. Moxifloxacin
15.7.2.2.2.3. Others
15.7.2.3. Japan Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.7.2.3.1. Oral
15.7.2.3.2. Parenteral
15.7.2.4. Japan Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
15.7.2.4.1. Tablets
15.7.2.4.2. Capsules
15.7.2.4.3. Powder for Solution for Injection
15.7.2.4.4. Others
15.7.2.5. Japan Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
15.7.2.5.1. Hospital Pharmacies
15.7.2.5.2. Retail Pharmacies
15.7.2.5.3. Online
15.7.2.5.4. Others
15.7.3. India
15.7.3.1. India Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Type of Tuberculosis
15.7.3.1.1. Active Tuberculosis
15.7.3.1.2. Latent Tuberculosis
15.7.3.2. India Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
15.7.3.2.1. First Line Drugs
15.7.3.2.1.1. Isoniazid
15.7.3.2.1.2. Rifampicin/
Rifampin
15.7.3.2.1.3. Ethambutol
15.7.3.2.1.4. Pyrazinamide
15.7.3.2.1.5. Others
15.7.3.2.2. Second Line Drugs
15.7.3.2.2.1. Levofloxacin
15.7.3.2.2.2. Moxifloxacin
15.7.3.2.2.3. Others
15.7.3.3. India Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.7.3.3.1. Oral
15.7.3.3.2. Parenteral
15.7.3.4. India Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
15.7.3.4.1. Tablets
15.7.3.4.2. Capsules
15.7.3.4.3. Powder for Solution for Injection
15.7.3.4.4. Others
15.7.3.5. India Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
15.7.3.5.1. Hospital Pharmacies
15.7.3.5.2. Retail Pharmacies
15.7.3.5.3. Online
15.7.3.5.4. Others
15.7.4. New
Zealand
15.7.4.1. New Zealand Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
15.7.4.1.1. Active Tuberculosis
15.7.4.1.2. Latent Tuberculosis
15.7.4.2. New Zealand Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
15.7.4.2.1. First Line Drugs
15.7.4.2.1.1. Isoniazid
15.7.4.2.1.2. Rifampicin/
Rifampin
15.7.4.2.1.3. Ethambutol
15.7.4.2.1.4. Pyrazinamide
15.7.4.2.1.5. Others
15.7.4.2.2. Second Line Drugs
15.7.4.2.2.1. Levofloxacin
15.7.4.2.2.2. Moxifloxacin
15.7.4.2.2.3. Others
15.7.4.3. New Zealand Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.7.4.3.1. Oral
15.7.4.3.2. Parenteral
15.7.4.4. New Zealand Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
15.7.4.4.1. Tablets
15.7.4.4.2. Capsules
15.7.4.4.3. Powder for Solution for Injection
15.7.4.4.4. Others
15.7.4.5. New Zealand Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.7.4.5.1. Hospital Pharmacies
15.7.4.5.2. Retail Pharmacies
15.7.4.5.3. Online
15.7.4.5.4. Others
15.7.5. Australia
15.7.5.1. Australia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
15.7.5.1.1. Active Tuberculosis
15.7.5.1.2. Latent Tuberculosis
15.7.5.2. Australia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
15.7.5.2.1. First Line Drugs
15.7.5.2.1.1. Isoniazid
15.7.5.2.1.2. Rifampicin/
Rifampin
15.7.5.2.1.3. Ethambutol
15.7.5.2.1.4. Pyrazinamide
15.7.5.2.1.5. Others
15.7.5.2.2. Second Line Drugs
15.7.5.2.2.1. Levofloxacin
15.7.5.2.2.2. Moxifloxacin
15.7.5.2.2.3. Others
15.7.5.3. Australia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.7.5.3.1. Oral
15.7.5.3.2. Parenteral
15.7.5.4. Australia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
15.7.5.4.1. Tablets
15.7.5.4.2. Capsules
15.7.5.4.3. Powder for Solution for Injection
15.7.5.4.4. Others
15.7.5.5. Australia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.7.5.5.1. Hospital Pharmacies
15.7.5.5.2. Retail Pharmacies
15.7.5.5.3. Online
15.7.5.5.4. Others
15.7.6. South
Korea
15.7.6.1. South Korea Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
15.7.6.1.1. Active Tuberculosis
15.7.6.1.2. Latent Tuberculosis
15.7.6.2. South Korea Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
15.7.6.2.1. First Line Drugs
15.7.6.2.1.1. Isoniazid
15.7.6.2.1.2. Rifampicin/
Rifampin
15.7.6.2.1.3. Ethambutol
15.7.6.2.1.4. Pyrazinamide
15.7.6.2.1.5. Others
15.7.6.2.2. Second Line Drugs
15.7.6.2.2.1. Levofloxacin
15.7.6.2.2.2. Moxifloxacin
15.7.6.2.2.3. Others
15.7.6.3. South Korea Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.7.6.3.1. Oral
15.7.6.3.2. Parenteral
15.7.6.4. South Korea Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
15.7.6.4.1. Tablets
15.7.6.4.2. Capsules
15.7.6.4.3. Powder for Solution for Injection
15.7.6.4.4. Others
15.7.6.5. South Korea Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.7.6.5.1. Hospital Pharmacies
15.7.6.5.2. Retail Pharmacies
15.7.6.5.3. Online
15.7.6.5.4. Others
15.7.7. Southeast
Asia
15.7.7.1. Southeast Asia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
15.7.7.1.1. Active Tuberculosis
15.7.7.1.2. Latent Tuberculosis
15.7.7.2. Southeast Asia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
15.7.7.2.1. First Line Drugs
15.7.7.2.1.1. Isoniazid
15.7.7.2.1.2. Rifampicin/
Rifampin
15.7.7.2.1.3. Ethambutol
15.7.7.2.1.4. Pyrazinamide
15.7.7.2.1.5. Others
15.7.7.2.2. Second Line Drugs
15.7.7.2.2.1. Levofloxacin
15.7.7.2.2.2. Moxifloxacin
15.7.7.2.2.3. Others
15.7.7.3. Southeast Asia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.7.7.3.1. Oral
15.7.7.3.2. Parenteral
15.7.7.4. Southeast Asia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
15.7.7.4.1. Tablets
15.7.7.4.2. Capsules
15.7.7.4.3. Powder for Solution for Injection
15.7.7.4.4. Others
15.7.7.5. Southeast Asia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.7.7.5.1. Hospital Pharmacies
15.7.7.5.2. Retail Pharmacies
15.7.7.5.3. Online
15.7.7.5.4. Others
15.7.7.6. Southeast Asia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest of Southeast Asia
15.7.8. Rest of
Asia Pacific
15.7.8.1. Rest of Asia Pacific Tuberculosis Drug Market Revenue (US$ Mn)
and Forecasts, By Type of Tuberculosis
15.7.8.1.1. Active Tuberculosis
15.7.8.1.2. Latent Tuberculosis
15.7.8.2. Rest of Asia Pacific Tuberculosis Drug Market Revenue (US$ Mn)
and Forecasts, By Treatment Type
15.7.8.2.1. First Line Drugs
15.7.8.2.1.1. Isoniazid
15.7.8.2.1.2. Rifampicin/
Rifampin
15.7.8.2.1.3. Ethambutol
15.7.8.2.1.4. Pyrazinamide
15.7.8.2.1.5. Others
15.7.8.2.2. Second Line Drugs
15.7.8.2.2.1. Levofloxacin
15.7.8.2.2.2. Moxifloxacin
15.7.8.2.2.3. Others
15.7.8.3. Rest of Asia Pacific Tuberculosis Drug Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.7.8.3.1. Oral
15.7.8.3.2. Parenteral
15.7.8.4. Rest of Asia Pacific Tuberculosis Drug Market Revenue (US$ Mn)
and Forecasts, By Dosage Form
15.7.8.4.1. Tablets
15.7.8.4.2. Capsules
15.7.8.4.3. Powder for Solution for Injection
15.7.8.4.4. Others
15.7.8.5. Rest of Asia Pacific Tuberculosis Drug Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
15.7.8.5.1. Hospital Pharmacies
15.7.8.5.2. Retail Pharmacies
15.7.8.5.3. Online
15.7.8.5.4. Others
15.8. Key
Segment for Channeling Investments
15.8.1. By
Country
15.8.2. By Type
of Tuberculosis
15.8.3. By
Treatment Type
15.8.4. By
Route of Administration
15.8.5. By
Dosage Form
15.8.6. By
Distribution Channel
16. Middle East and Africa Tuberculosis Drug Market Analysis and
Forecasts, 2020 - 2028
16.1. Overview
16.1.1. Middle
East and Africa Tuberculosis Drug Market Revenue (US$ Mn)
16.2. Middle
East and Africa Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By
Type of Tuberculosis
16.2.1. Active
Tuberculosis
16.2.2. Latent Tuberculosis
16.3. Middle
East and Africa Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
16.3.1. First
Line Drugs
16.3.1.1. Isoniazid
16.3.1.2. Rifampicin/ Rifampin
16.3.1.3. Ethambutol
16.3.1.4. Pyrazinamide
16.3.1.5. Others
16.3.2. Second
Line Drugs
16.3.2.1. Levofloxacin
16.3.2.2. Moxifloxacin
16.3.2.3. Others
16.4. Middle
East and Africa Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.4.1. Oral
16.4.2. Parenteral
16.5. Middle
East and Africa Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
16.5.1. Tablets
16.5.2. Capsules
16.5.3. Powder
for Solution for Injection
16.5.4. Others
16.6. Middle
East and Africa Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.6.1. Hospital
Pharmacies
16.6.2. Retail
Pharmacies
16.6.3. Online
16.6.4. Others
16.7. Middle
East and Africa Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By
Country
16.7.1. Saudi
Arabia
16.7.1.1. Saudi Arabia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
16.7.1.1.1. Active Tuberculosis
16.7.1.1.2. Latent Tuberculosis
16.7.1.2. Saudi Arabia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
16.7.1.2.1. First Line Drugs
16.7.1.2.1.1. Isoniazid
16.7.1.2.1.2. Rifampicin/
Rifampin
16.7.1.2.1.3. Ethambutol
16.7.1.2.1.4. Pyrazinamide
16.7.1.2.1.5. Others
16.7.1.2.2. Second Line Drugs
16.7.1.2.2.1. Levofloxacin
16.7.1.2.2.2. Moxifloxacin
16.7.1.2.2.3. Others
16.7.1.3. Saudi Arabia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.7.1.3.1. Oral
16.7.1.3.2. Parenteral
16.7.1.4. Saudi Arabia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
16.7.1.4.1. Tablets
16.7.1.4.2. Capsules
16.7.1.4.3. Powder for Solution for Injection
16.7.1.4.4. Others
16.7.1.5. Saudi Arabia Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
16.7.1.5.1. Hospital Pharmacies
16.7.1.5.2. Retail Pharmacies
16.7.1.5.3. Online
16.7.1.5.4. Others
16.7.2. UAE
16.7.2.1. UAE Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Type of Tuberculosis
16.7.2.1.1. Active Tuberculosis
16.7.2.1.2. Latent Tuberculosis
16.7.2.2. UAE Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
16.7.2.2.1. First Line Drugs
16.7.2.2.1.1. Isoniazid
16.7.2.2.1.2. Rifampicin/
Rifampin
16.7.2.2.1.3. Ethambutol
16.7.2.2.1.4. Pyrazinamide
16.7.2.2.1.5. Others
16.7.2.2.2. Second Line Drugs
16.7.2.2.2.1. Levofloxacin
16.7.2.2.2.2. Moxifloxacin
16.7.2.2.2.3. Others
16.7.2.3. UAE Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
16.7.2.3.1. Oral
16.7.2.3.2. Parenteral
16.7.2.4. UAE Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
16.7.2.4.1. Tablets
16.7.2.4.2. Capsules
16.7.2.4.3. Powder for Solution for Injection
16.7.2.4.4. Others
16.7.2.5. UAE Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
16.7.2.5.1. Hospital Pharmacies
16.7.2.5.2. Retail Pharmacies
16.7.2.5.3. Online
16.7.2.5.4. Others
16.7.3. Egypt
16.7.3.1. Egypt Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Type of Tuberculosis
16.7.3.1.1. Active Tuberculosis
16.7.3.1.2. Latent Tuberculosis
16.7.3.2. Egypt Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
16.7.3.2.1. First Line Drugs
16.7.3.2.1.1. Isoniazid
16.7.3.2.1.2. Rifampicin/
Rifampin
16.7.3.2.1.3. Ethambutol
16.7.3.2.1.4. Pyrazinamide
16.7.3.2.1.5. Others
16.7.3.2.2. Second Line Drugs
16.7.3.2.2.1. Levofloxacin
16.7.3.2.2.2. Moxifloxacin
16.7.3.2.2.3. Others
16.7.3.3. Egypt Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
16.7.3.3.1. Oral
16.7.3.3.2. Parenteral
16.7.3.4. Egypt Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
16.7.3.4.1. Tablets
16.7.3.4.2. Capsules
16.7.3.4.3. Powder for Solution for Injection
16.7.3.4.4. Others
16.7.3.5. Egypt Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
16.7.3.5.1. Hospital Pharmacies
16.7.3.5.2. Retail Pharmacies
16.7.3.5.3. Online
16.7.3.5.4. Others
16.7.4. Kuwait
16.7.4.1. Kuwait Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
16.7.4.1.1. Active Tuberculosis
16.7.4.1.2. Latent Tuberculosis
16.7.4.2. Kuwait Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
16.7.4.2.1. First Line Drugs
16.7.4.2.1.1. Isoniazid
16.7.4.2.1.2. Rifampicin/
Rifampin
16.7.4.2.1.3. Ethambutol
16.7.4.2.1.4. Pyrazinamide
16.7.4.2.1.5. Others
16.7.4.2.2. Second Line Drugs
16.7.4.2.2.1. Levofloxacin
16.7.4.2.2.2. Moxifloxacin
16.7.4.2.2.3. Others
16.7.4.3. Kuwait Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.7.4.3.1. Oral
16.7.4.3.2. Parenteral
16.7.4.4. Kuwait Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
16.7.4.4.1. Tablets
16.7.4.4.2. Capsules
16.7.4.4.3. Powder for Solution for Injection
16.7.4.4.4. Others
16.7.4.5. Kuwait Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
16.7.4.5.1. Hospital Pharmacies
16.7.4.5.2. Retail Pharmacies
16.7.4.5.3. Online
16.7.4.5.4. Others
16.7.5. South
Africa
16.7.5.1. South Africa Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
16.7.5.1.1. Active Tuberculosis
16.7.5.1.2. Latent Tuberculosis
16.7.5.2. South Africa Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
16.7.5.2.1. First Line Drugs
16.7.5.2.1.1. Isoniazid
16.7.5.2.1.2. Rifampicin/
Rifampin
16.7.5.2.1.3. Ethambutol
16.7.5.2.1.4. Pyrazinamide
16.7.5.2.1.5. Others
16.7.5.2.2. Second Line Drugs
16.7.5.2.2.1. Levofloxacin
16.7.5.2.2.2. Moxifloxacin
16.7.5.2.2.3. Others
16.7.5.3. South Africa Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.7.5.3.1. Oral
16.7.5.3.2. Parenteral
16.7.5.4. South Africa Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
16.7.5.4.1. Tablets
16.7.5.4.2. Capsules
16.7.5.4.3. Powder for Solution for Injection
16.7.5.4.4. Others
16.7.5.5. South Africa Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
16.7.5.5.1. Hospital Pharmacies
16.7.5.5.2. Retail Pharmacies
16.7.5.5.3. Online
16.7.5.5.4. Others
16.7.6. Rest of
Middle East & Africa
16.7.6.1. Rest of Middle East & Africa Tuberculosis Drug Market
Revenue (US$ Mn) and Forecasts, By Type of Tuberculosis
16.7.6.1.1. Active Tuberculosis
16.7.6.1.2. Latent Tuberculosis
16.7.6.2. Rest of Middle East & Africa Tuberculosis Drug Market
Revenue (US$ Mn) and Forecasts, By Treatment Type
16.7.6.2.1. First Line Drugs
16.7.6.2.1.1. Isoniazid
16.7.6.2.1.2. Rifampicin/
Rifampin
16.7.6.2.1.3. Ethambutol
16.7.6.2.1.4. Pyrazinamide
16.7.6.2.1.5. Others
16.7.6.2.2. Second Line Drugs
16.7.6.2.2.1. Levofloxacin
16.7.6.2.2.2. Moxifloxacin
16.7.6.2.2.3. Others
16.7.6.3. Rest of Middle East & Africa Tuberculosis Drug Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.6.3.1. Oral
16.7.6.3.2. Parenteral
16.7.6.4. Rest of Middle East & Africa Tuberculosis Drug Market
Revenue (US$ Mn) and Forecasts, By Dosage Form
16.7.6.4.1. Tablets
16.7.6.4.2. Capsules
16.7.6.4.3. Powder for Solution for Injection
16.7.6.4.4. Others
16.7.6.5. Rest of Middle East & Africa Tuberculosis Drug Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
16.7.6.5.1. Hospital Pharmacies
16.7.6.5.2. Retail Pharmacies
16.7.6.5.3. Online
16.7.6.5.4. Others
16.8. Key
Segment for Channeling Investments
16.8.1. By
Country
16.8.2. By Type
of Tuberculosis
16.8.3. By
Treatment Type
16.8.4. By
Route of Administration
16.8.5. By
Dosage Form
16.8.6. By
Distribution Channel
17. Latin America Tuberculosis Drug Market Analysis and
Forecasts, 2020 - 2028
17.1. Overview
17.1.1. Latin
America Tuberculosis Drug Market Revenue (US$ Mn)
17.2. Latin
America Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Type of
Tuberculosis
17.2.1. Active
Tuberculosis
17.2.2. Latent
Tuberculosis
17.3. Latin
America Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Treatment
Type
17.3.1. First
Line Drugs
17.3.1.1. Isoniazid
17.3.1.2. Rifampicin/ Rifampin
17.3.1.3. Ethambutol
17.3.1.4. Pyrazinamide
17.3.1.5. Others
17.3.2. Second
Line Drugs
17.3.2.1. Levofloxacin
17.3.2.2. Moxifloxacin
17.3.2.3. Others
17.4. Latin
America Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.4.1. Oral
17.4.2. Parenteral
17.5. Latin
America Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Dosage Form
17.5.1. Tablets
17.5.2. Capsules
17.5.3. Powder
for Solution for Injection
17.5.4. Others
17.6. Latin
America Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
17.6.1. Hospital
Pharmacies
17.6.2. Retail
Pharmacies
17.6.3. Online
17.6.4. Others
17.7. Latin
America Tuberculosis Drug Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1. Brazil Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
17.7.1.1.1. Active Tuberculosis
17.7.1.1.2. Latent Tuberculosis
17.7.1.2. Brazil Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
17.7.1.2.1. First Line Drugs
17.7.1.2.1.1. Isoniazid
17.7.1.2.1.2. Rifampicin/
Rifampin
17.7.1.2.1.3. Ethambutol
17.7.1.2.1.4. Pyrazinamide
17.7.1.2.1.5. Others
17.7.1.2.2. Second Line Drugs
17.7.1.2.2.1. Levofloxacin
17.7.1.2.2.2. Moxifloxacin
17.7.1.2.2.3. Others
17.7.1.3. Brazil Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
17.7.1.3.1. Oral
17.7.1.3.2. Parenteral
17.7.1.4. Brazil Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
17.7.1.4.1. Tablets
17.7.1.4.2. Capsules
17.7.1.4.3. Powder for Solution for Injection
17.7.1.4.4. Others
17.7.1.5. Brazil Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
17.7.1.5.1. Hospital Pharmacies
17.7.1.5.2. Retail Pharmacies
17.7.1.5.3. Online
17.7.1.5.4. Others
17.7.2. Argentina
17.7.2.1. Argentina Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Type of Tuberculosis
17.7.2.1.1. Active Tuberculosis
17.7.2.1.2. Latent Tuberculosis
17.7.2.2. Argentina Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
17.7.2.2.1. First Line Drugs
17.7.2.2.1.1. Isoniazid
17.7.2.2.1.2. Rifampicin/
Rifampin
17.7.2.2.1.3. Ethambutol
17.7.2.2.1.4. Pyrazinamide
17.7.2.2.1.5. Others
17.7.2.2.2. Second Line Drugs
17.7.2.2.2.1. Levofloxacin
17.7.2.2.2.2. Moxifloxacin
17.7.2.2.2.3. Others
17.7.2.3. Argentina Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
17.7.2.3.1. Oral
17.7.2.3.2. Parenteral
17.7.2.4. Argentina Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
17.7.2.4.1. Tablets
17.7.2.4.2. Capsules
17.7.2.4.3. Powder for Solution for Injection
17.7.2.4.4. Others
17.7.2.5. Argentina Tuberculosis Drug Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
17.7.2.5.1. Hospital Pharmacies
17.7.2.5.2. Retail Pharmacies
17.7.2.5.3. Online
17.7.2.5.4. Others
17.7.3. Rest of
Latin America
17.7.3.1. Rest of Latin America Tuberculosis Drug Market Revenue (US$
Mn) and Forecasts, By Type of Tuberculosis
17.7.3.1.1. Active Tuberculosis
17.7.3.1.2. Latent Tuberculosis
17.7.3.2. Rest of Latin America Tuberculosis Drug Market Revenue (US$
Mn) and Forecasts, By Treatment Type
17.7.3.2.1. First Line Drugs
17.7.3.2.1.1. Isoniazid
17.7.3.2.1.2. Rifampicin/
Rifampin
17.7.3.2.1.3. Ethambutol
17.7.3.2.1.4. Pyrazinamide
17.7.3.2.1.5. Others
17.7.3.2.2. Second Line Drugs
17.7.3.2.2.1. Levofloxacin
17.7.3.2.2.2. Moxifloxacin
17.7.3.2.2.3. Others
17.7.3.3. Rest of Latin America Tuberculosis Drug Market Revenue (US$
Mn) and Forecasts, By Route of Administration
17.7.3.3.1. Oral
17.7.3.3.2. Parenteral
17.7.3.4. Rest of Latin America Tuberculosis Drug Market Revenue (US$
Mn) and Forecasts, By Dosage Form
17.7.3.4.1. Tablets
17.7.3.4.2. Capsules
17.7.3.4.3. Powder for Solution for Injection
17.7.3.4.4. Others
17.7.3.5. Rest of Latin America Tuberculosis Drug Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
17.7.3.5.1. Hospital Pharmacies
17.7.3.5.2. Retail Pharmacies
17.7.3.5.3. Online
17.7.3.5.4. Others
17.8. Key
Segment for Channeling Investments
17.8.1. By
Country
17.8.2. By Type
of Tuberculosis
17.8.3. By
Treatment Type
17.8.4. By
Route of Administration
17.8.5. By
Dosage Form
17.8.6. By
Distribution Channel
18. Competitive Benchmarking
18.1. Market
Share Analysis, 2019
18.2. Global
Presence and Growth Strategies
18.2.1. Mergers
and Acquisitions
18.2.2. Product
Launches
18.2.3. Investments
Trends
18.2.4. R&D
Initiatives
19. Player Profiles
19.1. Brown
& Burk
19.1.1. Company
Details
19.1.2. Company
Overview
19.1.3. Product
Offerings
19.1.4. Key
Developments
19.1.5. Financial
Analysis
19.1.6. SWOT
Analysis
19.1.7. Business
Strategies
19.2. Cadila
Pharmaceuticals
19.2.1. Company
Details
19.2.2. Company
Overview
19.2.3. Product
Offerings
19.2.4. Key
Developments
19.2.5. Financial
Analysis
19.2.6. SWOT
Analysis
19.2.7. Business Strategies
19.3. Cipla Inc.
19.3.1. Company
Details
19.3.2. Company
Overview
19.3.3. Product
Offerings
19.3.4. Key
Developments
19.3.5. Financial
Analysis
19.3.6. SWOT
Analysis
19.3.7. Business
Strategies
19.4. Fresenius Kabi (Singapore) Pte
Ltd
19.4.1. Company
Details
19.4.2. Company
Overview
19.4.3. Product
Offerings
19.4.4. Key Developments
19.4.5. Financial
Analysis
19.4.6. SWOT
Analysis
19.4.7. Business
Strategies
19.5. GlaxoSmithKline plc.
19.5.1. Company
Details
19.5.2. Company
Overview
19.5.3. Product
Offerings
19.5.4. Key
Developments
19.5.5. Financial
Analysis
19.5.6. SWOT
Analysis
19.5.7. Business
Strategies
19.6. Johnson & Johnson Services,
Inc.
19.6.1. Company
Details
19.6.2. Company
Overview
19.6.3. Product
Offerings
19.6.4. Key
Developments
19.6.5. Financial
Analysis
19.6.6. SWOT
Analysis
19.6.7. Business
Strategies
19.7. LUPIN
19.7.1. Company
Details
19.7.2. Company
Overview
19.7.3. Product
Offerings
19.7.4. Key
Developments
19.7.5. Financial
Analysis
19.7.6. SWOT
Analysis
19.7.7. Business
Strategies
19.8. Macleods Pharmaceuticals Ltd.
19.8.1. Company
Details
19.8.2. Company
Overview
19.8.3. Product
Offerings
19.8.4. Key
Developments
19.8.5. Financial
Analysis
19.8.6. SWOT
Analysis
19.8.7. Business
Strategies
19.9. Mylan N.V.
19.9.1. Company
Details
19.9.2. Company
Overview
19.9.3. Product
Offerings
19.9.4. Key
Developments
19.9.5. Financial
Analysis
19.9.6. SWOT
Analysis
19.9.7. Business
Strategies
19.10. Novartis AG
19.10.1. Company
Details
19.10.2. Company
Overview
19.10.3. Product
Offerings
19.10.4. Key
Developments
19.10.5. Financial
Analysis
19.10.6. SWOT
Analysis
19.10.7. Business
Strategies
19.11. Otsuka Pharmaceutical Co., Ltd.
19.11.1.
Company Details
19.11.2.
Company Overview
19.11.3.
Product Offerings
19.11.4.
Key Developments
19.11.5.
Financial Analysis
19.11.6.
SWOT Analysis
19.11.7. Business
Strategies
19.12. RIEMSER Pharma GmbH
19.12.1.
Company Details
19.12.2.
Company Overview
19.12.3.
Product Offerings
19.12.4.
Key Developments
19.12.5.
Financial Analysis
19.12.6.
SWOT Analysis
19.12.7. Business
Strategies
19.13. Sanofi
19.13.1.
Company Details
19.13.2.
Company Overview
19.13.3.
Product Offerings
19.13.4.
Key Developments
19.13.5.
Financial Analysis
19.13.6.
SWOT Analysis
19.13.7. Business
Strategies
19.14. Sequella, Inc
19.14.1.
Company Details
19.14.2.
Company Overview
19.14.3.
Product Offerings
19.14.4.
Key Developments
19.14.5.
Financial Analysis
19.14.6.
SWOT Analysis
19.14.7. Business
Strategies
19.15. Strides Pharma Science Limited
19.15.1.
Company Details
19.15.2.
Company Overview
19.15.3.
Product Offerings
19.15.4.
Key Developments
19.15.5.
Financial Analysis
19.15.6.
SWOT Analysis
19.15.7. Business Strategies
19.16. Other
Market Participants
20. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
